Nadja PRANG-RICHARD has over 20 years’ experience in the development of biopharmaceuticals. She started her carrier in 1997 as Head of Laboratory at a CRO in Munich providing analytical services to the pharmaceutical industry. In 2002 Nadja joined Amgen, Munich as Head of Bioanalytical Development and QC. In 2005 she became Director of Global Bioanalytical Development in Merck-Serono, Rome. She was appointed Head of Biotech Product Development for Oncology & Emerging Therapies in 2007, responsible for CMC development and manufacturing for products in phase I-III and on the market (e.g. Erbitux®). End of 2008 she joined LFB SA in Paris as Program Director for Monoclonal Antibodies. Today she works as biopharmaceutical development expert in her own company TECObiosciences in the Munich area. Nadja supports BIOMUNEX as expert for CMC development and manufacturing.